Soleno Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for patients with rare diseases. Their lead candidate, Diazoxide Choline Controlled Release (DCCR), is being evaluated for the treatment of Prader-Willi Syndrome, a genetic disorder with no known cure. This promising therapy has shown positive results in clinical trials, giving hope to patients and their families. Soleno Therapeutics Inc. is committed to making a significant impact in the lives of those affected by rare diseases through their dedication to research and development.
